| [1] |
Shiboski CH, Shiboski SC, Seror R, et al.2016American College of Rheumatology/European League Against Rheumatism classification criteria for primary Sjogren’s syndrome[J].Ann Rheum Dis,2017,76(1): 9-16. |
| [2] |
Seror R, Bowman SJ, Brito-Zeron P, et al. EULAR Sjögren’s syndrome disease activity index (ESSDAI)[J].RMD Open,2015,1(1): e000022. |
| [3] |
张文, 厉小梅, 徐东, 等. 原发性干燥综合征诊疗规范[J].中华内科杂志,2020,59(4): 269-276. |
| [4] |
张文, 陈竹, 厉小梅, 等. 原发性干燥综合征诊疗规范[J].中华内科杂志,2023,62(9): 1059-1067. |
| [5] |
Trevisani VFM, Pasoto SG, Fernandes MLMS, et al. Recommendations from the Brazilian society of rheumatology for the diagnosis of Sjogren’s syndrome (Part I)[J].Adv Rheumatol,2019,59(1): 58. doi:10.1186/s42358-019-0102-8pmid:31852541 |
| [6] |
Jousse-Joulin S, D’Agostino MA, Nicolas C, et al. Video clip assessment of a salivary gland ultrasound scoring system in Sjögren’s syndrome using consensual definitions: an OMERACT ultrasound working group reliability exercise[J].Ann Rheum Dis,2019,78(7): 967-973. doi:10.1136/annrheumdis-2019-215024pmid:31036626 |
| [7] |
Ramos-Casals M, Brito-Zerón P, Bombardieri S, et al. EULAR recommendations for the management of Sjogren’s syndrome with topical and systemic therapies[J].Ann Rheum Dis,2020,79(1): 3-18. doi:10.1136/annrheumdis-2019-216114pmid:31672775 |
| [8] |
亚洲干眼协会中国分会, 海峡两岸医药卫生交流协会眼科学专业委员会眼表与泪液病学组, 中国医师协会眼科医师分会眼表与干眼学组, 等. 中国干眼专家共识:免疫性疾病相关性干眼(2021年)[J].中华眼科杂志,2021,57(12): 898-907. |
| [9] |
Trevisani VFM, Pugliesi A, Pasoto SG, et al. Recommendations for evaluation and diagnosis of extra-glandular manifestations of primary sjogren syndrome: results of an epidemiologic systematic review/meta-analysis and a consensus guideline from the Brazilian Society of Rheumatology (articular, pulmonary and renal)[J].Adv Rheumatol,2022,62(1):18. doi:10.1186/s42358-022-00248-1pmid:35650656 |
| [10] |
Yueting L, Lin Q, Jian X, et al. Long-term survival analysis of patients with primary Sjögren’s syndrome in China[J].Int J Rheum Dis,2024,27(9): e15284. |
| [11] |
Lee AS, Scofield RH, Hammitt KM, et al. Consensus guidelines for evaluation and management of pulmonary disease in Sjogren’s[J].Chest,2021,159(2): 683-698. |
| [12] |
Trevisani VFM, Pinheiro AC, de Magalhães Souza Fialho SC, et al. Recommendations for evaluation and diagnosis of extra-glandular manifestations of primary Sjogren syndrome: results of an epidemiologic systematic review/meta-analysis and a consensus guideline from the Brazilian society of rheumatology (hepatic, gastrointestinal and pancreatic)[J].Adv Rheumatol,2022,62(1): 35. |
| [13] |
Xu D, Fang J, Zhang S, et al. Efficacy and safety of telitacicept in primary Sjögren’s syndrome: a randomized, double-blind, placebo-controlled, phase 2 trial[J].Rheumatology (Oxford),2024,63(3): 698-705. |
| [14] |
Alunno A, Carubbi F, Bartoloni E, et al. The kaleidoscope of neurological manifestations in primary Sjögren’s syndrome[J].Clin Exp Rheumatol,2019,37 Suppl 118(3):192-198. |
| [15] |
Pugliesi A, Egypto DCSD, Duffles G, et al. Recommendations on cutaneous and hematological manifestations of Sjögren’s disease by the Brazilian Society of Rheumatology[J].Adv Rheumatol,2024,64(1): 51. doi:10.1186/s42358-024-00391-xpmid:38982553 |
| [16] |
中华中医药学会风湿病分会. 干燥综合征病证结合诊疗指南[J].中医杂志,2024,65(4): 434-444. |
| [17] |
Baldini C, Fulvio G, La Rocca G, et al. Update on the pathophysiology and treatment of primary Sjögren syndrome[J].Nat Rev Rheumatol,2024,20(8): 473-491. doi:10.1038/s41584-024-01135-3pmid:38982205 |